选择性清除CCR8+调节性T细胞通过树突状细胞增强肺癌细胞毒性T细胞的抗肿瘤免疫
在四种NSCLC荷瘤小鼠模型中,CCR8抗体与PD1抑制剂联合显著减少肿瘤生长(p < 0.05),且无明显小鼠体重下降和全身细胞因子风暴;机制上通过重塑肿瘤微环境、阻断CCR8+Treg与CCL5+树突状细胞相互作用并促进CD8+T细胞毒性活性实现协同;CCR8抗体LM-108联合免疫治疗的潜力在晚期NSCLC临床患者中被观察到。
要点
- CCR8抗体联合PD1抑制剂在四种NSCLC小鼠模型中显著减少肿瘤生长(p < 0.05),无明显体重下降和细胞因子风暴。
- 抗CCR8治疗通过重塑肿瘤微环境、阻断CCR8+Treg与CCL5+树突状细胞相互作用与PD1阻断协同。
- CCR8抗体LM-108联合免疫治疗的潜力在晚期NSCLC临床患者中被观察到。
核心结论
- 肿瘤浸润Treg细胞上的CCR8表达与对树突状细胞和CD8+T细胞的免疫抑制功能相关,从而阻碍抗肿瘤免疫。
研究设计与样本
- 在四种NSCLC荷瘤小鼠模型中评估抗CCR8单药及联合PD1抑制剂的疗效与安全性。
- 在不同治疗方案后第3、7、14、21天对肿瘤进行单细胞RNA测序、单细胞T细胞受体测序分析、流式细胞术、多色免疫荧光和Luminex检测。
- 应用体外和体内实验验证发现并探索协同效应的分子机制。
主要发现
- 在四种NSCLC荷瘤小鼠模型中,CCR8抗体与PD1抑制剂联合显著减少肿瘤生长(p < 0.05),无明显小鼠体重下降和全身细胞因子风暴。
- 抗CCR8治疗通过重塑肿瘤微环境并破坏CCR8+Treg与CCL5+树突状细胞相互作用与PD1阻断协同。
- 治疗性清除CCR8+Treg细胞联合PD1抑制剂通过激活CCL5+树突状细胞上的JAK-STAT通路极大增加白细胞介素-12分泌,从而促进CD8+T细胞的细胞毒性活性。
- CCR8抗体LM-108联合免疫治疗的潜力在晚期NSCLC临床患者中被观察到。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Accumulation of regulatory T (Treg) cells, an immunosuppressive population, limits the efficacy of immunotherapy in NSCLC. C-C motif chemokine receptor 8 (CCR8) is selectively expressed in tumor-infiltrating Treg cells and is, therefore, considered an ideal target. METHODS: The efficacy and safety of anti-CCR8 monotherapy and its combination with programmed cell death protein-1 (PD1) inhibitor were evaluated in four NSCLC-bearing mice models. To track the dynamic changes in tumor microenvironment, we performed the single-cell RNA sequencing, the single-cell T-cell receptor sequencing analysis, the flow cytometry, the multi-color immunofluorescence, and the Luminex assay on tumors after three, seven, 14, and 21 days of different treatment regimens. Then, in vitro and in vivo experiments were applied to validate our findings and explore molecular mechanisms of the synergistic effects. RESULTS: Across four NSCLC-bearing mice models, the combination of CCR8 antibody and PD1 inhibitor significantly reduced tumor growth (p < 0.05) without obvious mouse body weight drops and systemic cytokine storm. The anti-CCR8 therapy synergizes with PD1 blockade by remodeling the tumor microenvironment and disrupting CCR8+Treg-C-C motif chemokine ligand 5 (CCL5)+ dendritic cells (DC) interaction. Mechanistically, therapeutic depletion of CCR8+Treg cells combined with PD1 inhibitor extremely increased interleukin-12 secretion by the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway activation on CCL5+ DCs, thereby promoting cytotoxic activity of CD8+ T cells. The therapeutic potential of the CCR8 antibody LM-108 in combination with immunotherapy was observed in clinical patients with advanced NSCLC. CONCLUSION: Overall, CCR8 expression on tumor-infiltrating Treg cells is correlated with immunosuppressive function on DCs and CD8+ T cells, thus impeding antitumor immunity.
引用
- Chen P, Wang H, Tang Z, et al. Selective Depletion of CCR8+Treg Cells Enhances the Antitumor Immunity of Cytotoxic T Cells in Lung Cancer by Dendritic Cells. J Thorac Oncol. 2025. PMID: 40056978. doi:10.1016/j.jtho.2025.02.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。